Fluidigm made a splash with the markets on Wednesday morning after the company announced a critical update from the FDA in regards to its COVID-19 test.
After Fluidigm announced preliminary results for its third quarter on Wednesday, investors sent the shares sharply lower.
The top analyst upgrades, downgrades and initiations seen on Friday, February 5, include Coca-Cola, Goldman Sachs, JPMorgan, LinkedIn, Linn Energy, Tableau Software and Weatherford International.
Shares tumbled after Fluidigm reported disappointing second-quarter financial results and lowered guidance.
A new report from Cowen makes the case that a blood test that detects evidence of cancer in the circulation could soon replace the older more traditional biopsy methods.
Fluidigm, a California-based life science research device provider, has filed with the SEC to become public this morning. The offering shows a total proposed maximum aggregate price of $86,250,000....